Alpha 2.0
Login Register
» Articles » PMID: 33532667

DAPA-CKD: The Beginning of a New Era in Renal Protection

Overview
Journal JACC Basic Transl Sci
Date 2021 Feb 3
PMID 33532667
Citations 2
Authors
David Z I Cherney
Subodh Verma
Affiliations
Soon will be listed here.
Citing Articles

Cardiorenal syndrome: evolving concepts and pediatric knowledge gaps.

Kula A, Bartlett D Pediatr Nephrol. 2024; 40(3):651-660.

PMID: 39331078 DOI: 10.1007/s00467-024-06517-z.

A comparison of the utility of the urine dipstick and urine protein-to-creatinine ratio for predicting microalbuminuria in patients with non-diabetic lifestyle-related diseases -a comparison with diabetes.

Ogi M, Seto T, Wakabayashi Y BMC Nephrol. 2022; 23(1):377.

PMID: 36434544 PMC: 9700904. DOI: 10.1186/s12882-022-02974-6.

References
1.
Cherney D, Heerspink H, Frederich R, Maldonado M, Liu J, Pong A . Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020; 63(6):1128-1140. PMC: 7228910. DOI: 10.1007/s00125-020-05133-4. View
2.
Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View
3.
Muller M, Pruijm M, Bonny O, Burnier M, Zanchi A . Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol. Adv Ther. 2018; 35(6):875-885. PMC: 6015115. DOI: 10.1007/s12325-018-0708-y. View
4.
Cherney D, Dekkers C, Barbour S, Cattran D, Gafor A, Greasley P . Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020; 8(7):582-593. DOI: 10.1016/S2213-8587(20)30162-5. View
5.
Lytvyn Y, Bjornstad P, van Raalte D, Heerspink H, Cherney D . The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. Endocr Rev. 2019; 41(2). PMC: 7156849. DOI: 10.1210/endrev/bnz010. View